Authorized generics take strikes from GPhA, Dems

Share this article:
Bad news for authorized generics on two fronts.

First, a Generic Pharmaceutical Association (GPhA) study showed that authorized generics yield consumers few cost savings, and that any such savings come from higher brand product prices, not lower generic prices.

And second, three Democratic senators announced a bill to ban them outright.

The GPhA study concluded that when authorized generics are marketed during a 180-day exclusivity period for an independent generic company, they significantly reduce the incentives for independent generic firms to challenge brand-name patents and develop non-infringing processes.

The findings challenged the methodology, analysis and conclusions of a recent study by the Pharmaceutical Research and Manufacturers of America that reported discounts off brand prices up to 15.8% greater in markets with authorized generics than in those without them.

Meanwhile, Senate bill S. 3695 was introduced to ban “authorized generics” from launching during the first approved generic applicant's 180-day marketing exclusivity period. Backed by Senators John D. Rockefeller IV (D-WV), Charles Schumer (D-NY) and Patrick Leahy (D-VT), the measure is intended to prevent brand drug makers from re-packaging previously approved drugs as generics in an attempt to undermine generic competition.

“Authorized generics are a sham,” said Rockefeller. “They are nothing more than repackaged prescription drugs without true generic's lower cost,” and eliminate billions in prescription drug savings.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...